Retour
Retour

Laurence de Schoulepnikoff

Chief Operating Officer & Chief Business Officer
  • Management team

Laurence de Schoulepnikoff is a seasoned executive with over 25 years of experience and broad expertise in business development and transactions in the pharmaceutical industry, in particular in driving licensing transactions as well as acquisitions and divestments. Laurence joins OSE Immunotherapeutics from AMAL Therapeutics, a leading Swiss biotechnology company focused on therapeutic cancer vaccines acquired by Boehringer Ingelheim in 2019, where she spent the last three years as CBO and COO.

Prior to AMAL, Laurence worked in mid-sized companies (Ferring International, Stragen Pharma SA) as well as in large corporate organizations (Business Development at Novartis).

Laurence holds a Master’s degree in Chemical Engineering – École Polytechnique Fédérale of Lausanne (EPFL) – and is a Board member of the Swiss Healthcare Licensing Group (Swiss HLG).